D. E. Lopes de Menezes

发表

CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia

Yan Tang, Sang H. Lee, Yan Tang, 2005, Clinical Cancer Research.

A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.

M. Gleave, A. Tolcher, K. Chi, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models

Sang Hoon Lee, E. Samara, D. E. Lopes de Menezes, 2005, Clinical Cancer Research.

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes

P. Vyas, B. Skikne, G. Garcia-Manero, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.

L. Mayer, D. E. Lopes de Menezes, N. McIntosh, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Quantitative fluorescence cytometric analysis of Bcl-2 levels in tumor cells exhibiting a wide range of inherent Bcl-2 protein expression: correlation with Western blot analysis.

L. Mayer, D. E. Lopes de Menezes, W. Dragowska, 2000, Cytometry.

Recombinant Interleukin-2 Significantly Augments Activity of Rituximab in Human Tumor Xenograft Models of B-cell Non-Hodgkin Lymphoma

Yan Tang, J. Kunich, B. Jallal, 2007, Journal of immunotherapy.

Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status.

H. Döhner, F. Thol, H. Dombret, 2022, Blood.

CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons In vitro and In vivo

E. Moler, G. Schwartz, M. Embry, 2007, Clinical Cancer Research.

Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

H. Döhner, F. Thol, H. Dombret, 2021, Blood.

Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice.

Yanping Hu, L. Mayer, D. E. Lopes de Menezes, 2003, Journal of experimental therapeutics & oncology.

Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts

L. Mayer, D. E. Lopes de Menezes, 2001, Cancer Chemotherapy and Pharmacology.

Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo.

L. Pilarski, A. Belch, T. Allen, 2000, Biochimica et biophysica acta.

In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.

T M Allen, L. Pilarski, T. Allen, 1998, Cancer research.

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine

H. Döhner, F. Thol, H. Dombret, 2022, Blood.

Immunoliposome-mediated targeting of anti-cancer drugs in vivo.

I. Ahmad, E. Moase, T. Allen, 1995, Biochemical Society transactions.